IA
NTLA icon

IFP Advisors’s Intellia Therapeutics NTLA Stock Holding History

IFP Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Sell
1,492
-6
-0.4% -$84 ﹤0.01% 2834
2026
Q1 		$19.2K Buy
1,498
+705
+89% +$8.98K ﹤0.01% 2802
2025
Q4 		$7.13K Sell
793
-3
-0.4% -$41 ﹤0.01% 3233
2025
Q3 		$13.7K Buy
+796
New +$9.8K ﹤0.01% 2753
2025
Q2 		– Sell
-202
Closed -$1.66K – 2776
2025
Q1 		$1.44K Buy
202
+181
+862% +$1.83K ﹤0.01% 3249
2024
Q4 		$245 Buy
+21
New +$328 ﹤0.01% 3638
2024
Q3 		– Sell
-1
Closed -$22 – 3402
2024
Q2 		$22 Buy
+1
New +$24 ﹤0.01% 3201
2023
Q3 		– Sell
-35
Closed -$1.43K – 3475
2023
Q2 		$1.43K Buy
+35
New +$1.42K ﹤0.01% 2979
2023
Q1 		– Sell
-228
Closed -$6K – 4084
2022
Q4 		$6K Sell
228
-50
-18% -$2.38K ﹤0.01% 3709
2022
Q3 		$22K Hold
278
– – ﹤0.01% 3004
2022
Q2 		$22K Hold
278
– – ﹤0.01% 2762
2022
Q1 		$22K Buy
278
+257
+1,224% +$21.8K ﹤0.01% 2761
2021
Q4 		$3K Buy
+21
New +$2.63K ﹤0.01% 2679
2019
Q4 		– Sell
-215
Closed -$2.99K – 3027
2019
Q3 		$3K Buy
+215
New +$3.43K ﹤0.01% 2558
2019
Q1 		$4K Sell
215
-1,000
-82% -$14.9K ﹤0.01% 1941
2018
Q4 		$16K Buy
1,215
+250
+26% +$4.65K ﹤0.01% 2253
2018
Q3 		$28K Sell
965
-915
-49% -$26.6K ﹤0.01% 2255
2018
Q2 		$51K Buy
1,880
+130
+7% +$3.15K ﹤0.01% 1893
2018
Q1 		$34K Hold
1,750
– – ﹤0.01% 2036
2017
Q4 		$34K Buy
1,750
+1,460
+503% +$33.7K ﹤0.01% 2061
2017
Q3 		$7K Buy
290
+50
+21% +$942 ﹤0.01% 3228
2017
Q2 		$4K Hold
240
– – ﹤0.01% 3516
2017
Q1 		$3K Hold
240
– – ﹤0.01% 3548
2016
Q4 		$3K Hold
240
– – ﹤0.01% 3527
2016
Q3 		$4K Buy
+240
New +$4.64K ﹤0.01% 3347

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IFP Advisors's NTLA Position: Q2 2026 in Review

IFP Advisors reduced its Intellia Therapeutics (NTLA) stake by 0.4% in Q2 2026, selling an estimated $84 and leaving 1,492 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

IFP Advisors first reported a position in NTLA in Q3 2016 and has held it in 25 quarters since. The position peaked at $51K in Q2 2018. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IFP Advisors held 1,492 shares of Intellia Therapeutics worth $25.2K as of Q2 2026.
  • IFP Advisors sold 6 Intellia Therapeutics shares in Q2 2026, an estimated $84.
  • Intellia Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2834 holding.
  • IFP Advisors first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 25 quarters since.
  • IFP Advisors's Intellia Therapeutics position peaked at $51K in Q2 2018.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.